About this trial

This is a prospective, single-blind, randomized parallel study to investigate whether B. subtilis could improve clinical symptoms of IBS-D patients. Patients are randomly assigned by envelope method. A senior gastroenterologist is responsible for prescribing medication. Researchers are blind to patients' medication. Participants with IBS are recruited and randomized to receive a 4-week administration of B. subtilis-based probiotics. Clinical symptoms and stool samples are collected before and after the trial.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • B. subtilis
  • Dead B. subtilis

Treatment groups

180 Participants
are divided into 2 treatment groups

Locations

2
Jinling Hospital Nanjing China
Jinling Hospital Nanjing China

Sponsors and collaborators

Jinling Hospital, China

Lead sponsor